CN107073100B - Fmdv重组疫苗及其用途 - Google Patents

Fmdv重组疫苗及其用途 Download PDF

Info

Publication number
CN107073100B
CN107073100B CN201580057248.4A CN201580057248A CN107073100B CN 107073100 B CN107073100 B CN 107073100B CN 201580057248 A CN201580057248 A CN 201580057248A CN 107073100 B CN107073100 B CN 107073100B
Authority
CN
China
Prior art keywords
ala
thr
leu
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580057248.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107073100A (zh
Inventor
J-C·奥多奈特
Z·汉那斯-迪耶巴拉
T·梅巴特松
蒋有为
J·怀德纳
F·瑞那德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of CN107073100A publication Critical patent/CN107073100A/zh
Application granted granted Critical
Publication of CN107073100B publication Critical patent/CN107073100B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580057248.4A 2014-09-23 2015-09-23 Fmdv重组疫苗及其用途 Active CN107073100B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462054073P 2014-09-23 2014-09-23
US62/054,073 2014-09-23
PCT/US2015/051755 WO2016049209A1 (en) 2014-09-23 2015-09-23 Fmdv recombinant vaccines and uses thereof

Publications (2)

Publication Number Publication Date
CN107073100A CN107073100A (zh) 2017-08-18
CN107073100B true CN107073100B (zh) 2021-02-26

Family

ID=54256845

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580057248.4A Active CN107073100B (zh) 2014-09-23 2015-09-23 Fmdv重组疫苗及其用途

Country Status (19)

Country Link
US (1) US10010605B2 (cg-RX-API-DMAC10.html)
EP (2) EP4778534A2 (cg-RX-API-DMAC10.html)
JP (1) JP6931327B2 (cg-RX-API-DMAC10.html)
KR (1) KR102526219B1 (cg-RX-API-DMAC10.html)
CN (1) CN107073100B (cg-RX-API-DMAC10.html)
AP (1) AP2017009834A0 (cg-RX-API-DMAC10.html)
AR (1) AR102006A1 (cg-RX-API-DMAC10.html)
AU (2) AU2015320673B2 (cg-RX-API-DMAC10.html)
CA (1) CA2962225A1 (cg-RX-API-DMAC10.html)
DK (1) DK3197486T3 (cg-RX-API-DMAC10.html)
ES (1) ES3074144T3 (cg-RX-API-DMAC10.html)
JO (1) JO3600B1 (cg-RX-API-DMAC10.html)
MA (1) MA40151B2 (cg-RX-API-DMAC10.html)
MX (1) MX388708B (cg-RX-API-DMAC10.html)
PY (1) PY1548374A (cg-RX-API-DMAC10.html)
RU (1) RU2745373C2 (cg-RX-API-DMAC10.html)
TW (1) TWI733653B (cg-RX-API-DMAC10.html)
WO (1) WO2016049209A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201701851B (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3347044B1 (en) * 2015-09-10 2023-04-19 Academia Sinica Bird flu vaccine combination comprising virus-like particles and novel adjuvants
JP6797206B2 (ja) 2015-11-23 2020-12-09 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド Ｆｍｄｖ及びｅ２融合タンパク質並びにその使用
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
US10172933B2 (en) * 2016-10-31 2019-01-08 The United States Of America, As Represented By The Secretary Of Agriculture Mosaic vaccines for serotype a foot-and-mouth disease virus
JP7083362B2 (ja) * 2017-07-12 2022-06-10 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド セネカウイルスａ免疫原性組成物およびその方法
CN108103034B (zh) * 2017-12-15 2022-06-24 云南农业大学动物医学院 同时表达A型、O型和Asia-1型口蹄疫病毒VP1基因重组腺病毒、构建方法及应用
CN108530522B (zh) * 2018-03-14 2021-09-17 中华人民共和国汕头海关 一种重组的OmpK多表位多肽、构建方法及其应用
CN110467654B (zh) * 2018-05-11 2022-08-09 普莱柯生物工程股份有限公司 口蹄疫病毒样颗粒抗原、其制备的疫苗组合物及其制备方法和应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
US12226472B2 (en) * 2019-01-15 2025-02-18 Pulike Biological Engineering, Inc. Foot-and-mouth disease virus-like particle antigen, and vaccine composition, preparation method, and application thereof
WO2020263062A1 (ko) * 2019-06-28 2020-12-30 (주)플럼라인생명과학 구제역 바이러스 백신 조성물
JP2023549461A (ja) * 2020-10-22 2023-11-27 インターベット インターナショナル ベー． フェー． バキュロウイルス発現ベクター
CN116685687A (zh) * 2020-10-22 2023-09-01 英特维特国际股份有限公司 杆状病毒表达载体
US12453767B2 (en) 2021-08-18 2025-10-28 The United States Of America, As Represented By The Secretary Of Agriculture Development of mosaic vaccines against foot and mouth disease virus serotype O
IL310903A (en) * 2021-08-20 2024-04-01 Intervet Int Bv Method of producing a foot and mouth disease virus virus-like particle
EP4387665A1 (en) * 2021-08-20 2024-06-26 The Pirbright Institute Fmdv virus-like particle with double stabilizing mutation
IL310908A (en) * 2021-08-20 2024-04-01 Intervet Int Bv A virus-like FMDV particle with a stabilizing mutation
EP4387661A1 (en) * 2021-08-20 2024-06-26 Intervet International B.V. Method of producing a foot and mouth disease virus virus-like particle
KR102513632B1 (ko) * 2021-11-30 2023-03-28 주식회사 왓슨알앤디 구제역 바이러스 유사 입자를 생산하기 위한 백신 플랫폼
US12036318B2 (en) * 2022-02-16 2024-07-16 Chemical & Schutz High Performance Lubricants, S.A. De C.V. Self-emulsionable mineral oil as a vehicle in vaccines for poultry
EP4628096A1 (en) 2022-11-23 2025-10-08 Optipharm Co., Ltd. Recombinant expression vector for preparing foot-and-mouth disease virus-like particles or nanoparticles, and vaccine composition using same
WO2024112115A1 (ko) * 2022-11-23 2024-05-30 주식회사 옵티팜 구제역 바이러스 유사 입자 또는 나노입자 생산을 위한 재조합 발현 벡터 및 이를 이용한 백신 조성물
CN117210501B (zh) * 2023-09-13 2024-06-07 中国农业科学院兰州兽医研究所 口蹄疫病毒2b蛋白免疫抑制位点突变的重组口蹄疫病毒株的构建
CN117304277B (zh) * 2023-09-26 2024-03-08 中国农业科学院兰州兽医研究所 一种o型口蹄疫病毒vp4蛋白t细胞表位多肽及其应用
US20250134984A1 (en) * 2023-10-26 2025-05-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of mosaic vaccines against foot and mouth disease virus serotype asia
WO2026162694A1 (en) * 2025-02-01 2026-08-06 The Chancellor, Masters And Scholars Of The University Of Oxford Fmdv virus-like particle with stabilizing mutations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000251A1 (fr) * 2000-06-29 2002-01-03 Merial Vaccin contre la fievre aphteuse
CN101270155A (zh) * 2008-05-06 2008-09-24 中国农业科学院兰州兽医研究所 通过耐酸性改造在昆虫中组装口蹄疫病毒空衣壳的方法
CN103687614A (zh) * 2010-03-12 2014-03-26 梅里亚有限公司 口蹄疫病毒重组疫苗和其使用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
ZA915593B (en) 1990-07-24 1993-03-31 Novagene Inc Herpesvirus-based viral vector which expresses a foot and mounth disease virus epitope on the surface of virus-infected cells and on the surface of virus particles,and vaccine against foot and mounth disease containing the same
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
PL1651265T3 (pl) 2003-07-24 2008-10-31 Merial Ltd Formulacje szczepionek zawierających emulsję olej w wodzie
US7527960B2 (en) 2004-06-25 2009-05-05 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
WO2007059461A2 (en) 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
US20100285056A1 (en) * 2008-01-09 2010-11-11 Konkuk University Industrial Cooperation Corp. Baculovirus-Based Vaccines
GB0810710D0 (en) * 2008-06-11 2008-07-16 Animal Health Inst Vaccine
DK2475384T3 (en) 2009-09-10 2016-10-24 Merial Inc NEW VACCINE FORMULATIONS COMPREHENSIVE saponin-CONTAINING ADJUVANTS
RS56748B1 (sr) * 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
GB201111183D0 (en) * 2011-06-30 2011-08-17 Animal Health Inst Peptide
US20150183835A1 (en) * 2012-06-18 2015-07-02 Novartis Ag Stabilized gp120
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000251A1 (fr) * 2000-06-29 2002-01-03 Merial Vaccin contre la fievre aphteuse
CN101270155A (zh) * 2008-05-06 2008-09-24 中国农业科学院兰州兽医研究所 通过耐酸性改造在昆虫中组装口蹄疫病毒空衣壳的方法
CN103687614A (zh) * 2010-03-12 2014-03-26 梅里亚有限公司 口蹄疫病毒重组疫苗和其使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine;Diana M. Alejo等;《Vaccine》;20130401;第31卷(第18期);第2302-2309页 *
B. Mohana Subramanian等.Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency.《Antiviral Research》.2012,第96卷(第3期),第288-295页. *
Claudine Porta等.Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity.《JOURNAL OF VIROLOGICAL METHODS》.2012,第187卷(第2期),第406-412页. *
Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency;B. Mohana Subramanian等;《Antiviral Research》;20121006;第96卷(第3期);第288-295页 *
Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity;Claudine Porta等;《JOURNAL OF VIROLOGICAL METHODS》;20121119;第187卷(第2期);第402-416页 *
Recombinant adenovirus expressing type Asia1 foot-and-mouth disease virus capsid proteins induces protective immunity against homologous virus challenge in mice;Guohui Zhou等;《Research in Veterinary Science》;20130601;第94卷(第3期);第796-802页 *

Also Published As

Publication number Publication date
CN107073100A (zh) 2017-08-18
RU2017113571A (ru) 2018-10-26
ES3074144T3 (es) 2026-07-17
AU2019210537A1 (en) 2019-08-15
MX2017003712A (es) 2017-06-28
AR102006A1 (es) 2017-01-25
RU2745373C2 (ru) 2021-03-24
CA2962225A1 (en) 2016-03-31
TWI733653B (zh) 2021-07-21
EP3197486B1 (en) 2026-04-15
AU2015320673B2 (en) 2019-05-02
JP6931327B2 (ja) 2021-09-01
US10010605B2 (en) 2018-07-03
EP4778534A2 (en) 2026-07-22
MX388708B (es) 2025-03-20
RU2017113571A3 (cg-RX-API-DMAC10.html) 2019-04-22
BR112017005833A8 (pt) 2023-02-14
DK3197486T3 (da) 2026-06-29
JO3600B1 (ar) 2020-07-05
EP3197486B8 (en) 2026-05-27
TW201625297A (zh) 2016-07-16
PY1548374A (es) 2018-01-01
KR20170058430A (ko) 2017-05-26
AP2017009834A0 (en) 2017-03-31
AU2015320673A1 (en) 2017-05-11
MA40151B2 (fr) 2022-12-30
BR112017005833A2 (pt) 2018-02-27
US20160220659A1 (en) 2016-08-04
MA40151A1 (fr) 2018-01-31
EP3197486A1 (en) 2017-08-02
JP2017530124A (ja) 2017-10-12
KR102526219B1 (ko) 2023-04-26
WO2016049209A1 (en) 2016-03-31
ZA201701851B (en) 2018-05-30

Similar Documents

Publication Publication Date Title
KR102526219B1 (ko) Ｆｍｄｖ 재조합 백신 및 이의 용도
CN108779474B (zh) 以重组腺病毒为载体的fmdv疫苗及其用途
JP6818748B2 (ja) イヌパルボウイルス（ｃｐｖ）ウイルス様粒子（ｖｌｐ）ワクチン及びその使用
JP6797206B2 (ja) Ｆｍｄｖ及びｅ２融合タンパク質並びにその使用
ES2386373T3 (es) Vacuna contra la fiebre aftosa
JP2015525076A (ja) 再集合体ｂｔｖおよびａｈｓｖワクチン
BR112017005833B1 (pt) Vacinas recombinantes fmdv e seus usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190711

Address after: Georgia

Applicant after: Bollinger Ingham Animal Health USA

Address before: Georgia

Applicant before: Cimmeria limited-liability company

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant